<p>Microbot Medical Inc.（納斯達克代碼：MBOT - 獲取免費報告）在九月份的空頭頭寸出現了大幅下降。截至九月三十日，空頭頭寸總計為 4,540,000 股，較九月十五日的 10,630,000 股下降了 57.3%。根據平均每日交易量 4,200,000 股，目前的覆蓋天數比率為 1.1 天。</p>
<p>獲取 <strong>Microbot Medical</strong> 警報：</p>
<h2>對 Microbot Medical 的對沖基金看法</h2>
<ul>
<li>Intuitive Surgical 在其 52 周高點提供了買入機會</li>
</ul>
<p>大型投資者最近買入和賣出了該公司的股票。美國資本財富顧問公司在第二季度購買了 Microbot Medical 的新頭寸，價值 25,000 美元。美國世紀公司在第二季度購買了 Microbot Medical 的新頭寸，價值 32,000 美元。Beacon Capital Management LLC 在第二季度將其在 Microbot Medical 的頭寸提高了 166.7%。Beacon Capital Management LLC 現在擁有 16,000 股該生物技術公司的股票，價值 40,000 美元，此前在上個季度又購買了 10,000 股。Virtu Financial LLC 在第一季度購買了 Microbot Medical 的新頭寸，價值 42,000 美元。最後，XTX Topco Ltd 在第二季度購買了 Microbot Medical 的新頭寸，價值 43,000 美元。對沖基金和其他機構投資者擁有該公司 16.30% 的股票。</p>
<h2>Microbot Medical 價格表現</h2>
<p>MBOT 股票在週五開盤價為 2.76 美元。該公司的 50 日移動平均價格為 3.38 美元，200 日移動平均價格為 2.79 美元。Microbot Medical 的 12 個月低點為 0.89 美元，12 個月高點為 4.67 美元。該公司的市值為 1.8536 億美元，市盈率為-4.76，貝塔值為 1.25。</p>
<ul>
<li>Microbot Medical 因其血管內手術機器人股價飆升 150%</li>
</ul>
<p>Microbot Medical（納斯達克代碼：MBOT - 獲取免費報告）最後一次公佈季度財報是在 8 月 12 日（星期二）。該生物技術公司報告的季度每股收益為（0.10 美元），低於分析師一致預期的（0.08 美元）2 美分。整體來看，分析師預計 Microbot Medical 在當前年度的每股收益為-0.71 美元。</p>
<h2>分析師評級變動</h2>
<p>幾家券商最近對 MBOT 進行了評估。HC Wainwright 在週三的研究報告中重申了 “買入” 評級，並設定了 12.00 美元的目標價。華爾街 Zen 在 10 月 3 日（星期五）的研究報告中將 Microbot Medical 的股票評級從 “賣出” 上調至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了 Microbot Medical 的 “賣出（d-）” 評級。最後，Zacks Research 在 8 月 21 日（星期四）的研究報告中將 Microbot Medical 的股票評級從 “強力買入” 下調至 “持有”。一位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “持有”，平均目標價為 12.00 美元。</p>
<p><strong>閲讀我們關於 Microbot Medical 的最新報告</strong></p>
<h2>關於 Microbot Medical</h2>
<p>（獲取免費報告）</p>
<p>Microbot Medical Inc 是一家臨牀前醫療設備公司，專注於針對微創手術領域的機器人內腔手術設備的研究、設計和開發。該公司提供 LIBERTY，一種血管內機器人手術系統，允許醫生在導管實驗室外進行導管基礎程序，避免輻射暴露、身體負擔和交叉污染的風險，適用於心血管、外周和神經血管領域。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Microbot Medical 更好</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>強生的併購策略才是投資者真正關注的故事</li>
<li>為什麼這些公司被認為是藍籌股？</li>
<li>特斯拉：一些分析師預測將下跌 30%——該恐慌嗎？</li>
<li>最具波動性的股票，投資者需要知道的事項</li>
<li>對沖基金對美元的態度轉變——這三隻股票的買入信號？</li>
</ul>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Microbot Medical 嗎？</h2>
<p>在考慮 Microbot Medical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Microbot Medical 並不在名單上。</p>
<p>雖然 Microbot Medical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>查看這五隻股票</p>

MBOT

<p>Microbot Medical Inc.（納斯達克代碼：MBOT）在空頭頭寸方面經歷了顯著下降，截至 9 月 30 日，空頭頭寸從 10,630,000 股下降至 4,540,000 股，降幅為 57.3%。目前的空頭頭寸比率為 1.1 天，基於平均每日交易量為 4,200,000 股。該股票開盤價為 2.76 美元，市值為 1.8536 億美元。分析師的評級意見不一，普遍評級為 “持有”，平均目標價為 12.00 美元。該公司專注於開發用於微創手術的機器人內腔手術設備</p>

<p>Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) was the target of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 4,540,000 shares, a decline of 57.3% from the September 15th total of 10,630,000 shares. Based on an average daily trading volume, of 4,200,000 shares, the days-to-cover ratio is presently 1.1 days. Based on an average daily trading volume, of 4,200,000 shares, the days-to-cover ratio is presently 1.1 days.</p>
<div class="lb-trans"><p>Microbot Medical Inc.（納斯達克代碼：MBOT - 獲取免費報告）在九月份的空頭頭寸出現了大幅下降。截至九月三十日，空頭頭寸總計為 4,540,000 股，較九月十五日的 10,630,000 股下降了 57.3%。根據平均每日交易量 4,200,000 股，目前的覆蓋天數比率為 1.1 天。</p>
</div><p>Get <strong>Microbot Medical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Microbot Medical</strong> 警報：</p>
</div><h2>Hedge Funds Weigh In On Microbot Medical</h2>
<div class="lb-trans"><h2>對 Microbot Medical 的對沖基金看法</h2>
</div><ul>
<li>Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs</li>
</ul>
<div class="lb-trans"><ul>
<li>Intuitive Surgical 在其 52 周高點提供了買入機會</li>
</ul>
</div><p>Large investors have recently bought and sold shares of the company. U.S. Capital Wealth Advisors LLC purchased a new position in Microbot Medical during the 2nd quarter worth $25,000. American Century Companies Inc. purchased a new position in Microbot Medical during the 2nd quarter worth $32,000. Beacon Capital Management LLC raised its position in Microbot Medical by 166.7% during the 2nd quarter. Beacon Capital Management LLC now owns 16,000 shares of the biotechnology company's stock worth $40,000 after buying an additional 10,000 shares during the last quarter. Virtu Financial LLC purchased a new position in Microbot Medical during the 1st quarter worth $42,000. Finally, XTX Topco Ltd purchased a new position in Microbot Medical during the 2nd quarter worth $43,000. Hedge funds and other institutional investors own 16.30% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近買入和賣出了該公司的股票。美國資本財富顧問公司在第二季度購買了 Microbot Medical 的新頭寸，價值 25,000 美元。美國世紀公司在第二季度購買了 Microbot Medical 的新頭寸，價值 32,000 美元。Beacon Capital Management LLC 在第二季度將其在 Microbot Medical 的頭寸提高了 166.7%。Beacon Capital Management LLC 現在擁有 16,000 股該生物技術公司的股票，價值 40,000 美元，此前在上個季度又購買了 10,000 股。Virtu Financial LLC 在第一季度購買了 Microbot Medical 的新頭寸，價值 42,000 美元。最後，XTX Topco Ltd 在第二季度購買了 Microbot Medical 的新頭寸，價值 43,000 美元。對沖基金和其他機構投資者擁有該公司 16.30% 的股票。</p>
</div><h2>Microbot Medical Price Performance</h2>
<div class="lb-trans"><h2>Microbot Medical 價格表現</h2>
</div><p>MBOT stock opened at $2.76 on Friday. The company has a fifty day moving average price of $3.38 and a 200 day moving average price of $2.79. Microbot Medical has a 12 month low of $0.89 and a 12 month high of $4.67. The company has a market cap of $185.36 million, a price-to-earnings ratio of -4.76 and a beta of 1.25.</p>
<div class="lb-trans"><p>MBOT 股票在週五開盤價為 2.76 美元。該公司的 50 日移動平均價格為 3.38 美元，200 日移動平均價格為 2.79 美元。Microbot Medical 的 12 個月低點為 0.89 美元，12 個月高點為 4.67 美元。該公司的市值為 1.8536 億美元，市盈率為-4.76，貝塔值為 1.25。</p>
</div><ul>
<li>Microbot Medical spikes 150% on its Endovascular Surgical Robot</li>
</ul>
<div class="lb-trans"><ul>
<li>Microbot Medical 因其血管內手術機器人股價飆升 150%</li>
</ul>
</div><p>Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.02). As a group, analysts anticipate that Microbot Medical will post -0.71 earnings per share for the current year.</p>
<div class="lb-trans"><p>Microbot Medical（納斯達克代碼：MBOT - 獲取免費報告）最後一次公佈季度財報是在 8 月 12 日（星期二）。該生物技術公司報告的季度每股收益為（0.10 美元），低於分析師一致預期的（0.08 美元）2 美分。整體來看，分析師預計 Microbot Medical 在當前年度的每股收益為-0.71 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several brokerages have recently weighed in on MBOT. HC Wainwright restated a &#34;buy&#34; rating and set a $12.00 price objective on shares of Microbot Medical in a research report on Wednesday. Wall Street Zen upgraded shares of Microbot Medical from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Microbot Medical in a research report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Microbot Medical from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, August 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and an average target price of $12.00.</p>
<div class="lb-trans"><p>幾家券商最近對 MBOT 進行了評估。HC Wainwright 在週三的研究報告中重申了 “買入” 評級，並設定了 12.00 美元的目標價。華爾街 Zen 在 10 月 3 日（星期五）的研究報告中將 Microbot Medical 的股票評級從 “賣出” 上調至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了 Microbot Medical 的 “賣出（d-）” 評級。最後，Zacks Research 在 8 月 21 日（星期四）的研究報告中將 Microbot Medical 的股票評級從 “強力買入” 下調至 “持有”。一位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “持有”，平均目標價為 12.00 美元。</p>
</div><p><strong>Read Our Latest Report on Microbot Medical</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Microbot Medical 的最新報告</strong></p>
</div><h2>About Microbot Medical</h2>
<div class="lb-trans"><h2>關於 Microbot Medical</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.</p>
<div class="lb-trans"><p>Microbot Medical Inc 是一家臨牀前醫療設備公司，專注於針對微創手術領域的機器人內腔手術設備的研究、設計和開發。該公司提供 LIBERTY，一種血管內機器人手術系統，允許醫生在導管實驗室外進行導管基礎程序，避免輻射暴露、身體負擔和交叉污染的風險，適用於心血管、外周和神經血管領域。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Microbot Medical</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
<li>Why Are These Companies Considered Blue Chips?</li>
<li>Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Microbot Medical 更好</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>強生的併購策略才是投資者真正關注的故事</li>
<li>為什麼這些公司被認為是藍籌股？</li>
<li>特斯拉：一些分析師預測將下跌 30%——該恐慌嗎？</li>
<li>最具波動性的股票，投資者需要知道的事項</li>
<li>對沖基金對美元的態度轉變——這三隻股票的買入信號？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Microbot Medical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Microbot Medical 嗎？</h2>
</div><p>Before you consider Microbot Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Microbot Medical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Microbot Medical 並不在名單上。</p>
</div><p>While Microbot Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Microbot Medical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Microbot Medical Inc.（NASDAQ:MBOT）的空頭頭寸減少了 57.3%